Webinar Recap: Kappa and Lambda Free Light Chains in Plasma Cell Disorders
22nd Apr 2026
Abbott recently hosted a webinar exploring the clinical role of kappa and lambda free light chain testing in the diagnosis and monitoring of plasma cell disorders such as multiple myeloma.
Key points include the use of the kappa/lambda ratio to identify abnormal monoclonal protein production and how free light chain assays complement serum protein electrophoresis and immunofixation to support more
…
Diazyme Laboratories, Inc. Announces FDA 501(k) Clearance for MGUS for Kappa and Lambda Free Light Chain Assays
14th Jan 2026
SAN DIEGO, CA - January 14, 2026 - Diazyme Laboratories, Inc. announces receiving 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the evaluation of monoclonal gammopathy of undetermined significance (MGUS) for Diazyme’s Kappa and Lambda Free Light Chain Assays.
“FDA 510(k) clearance of added indication to our free light chain kappa and lambda assays demonstra
…
FDA Grants 510(k) Clearance to the Diazyme Colorimetric Lithium Assay
30th Dec 2025
SAN DIEGO, CA - 30 December 2025 - Diazyme Laboratories, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted 510(K) clearances to market the Diazyme Colorimetric Lithium Assay.
Diazyme Colorimetric Lithium Assay kit is for quantitative in vitro determination of lithium in human serum or EDTA plasma. Measurements of Lithium are carried out to ensure that proper drug do
…
Next-Generation Lithium Testing: Diazyme’s Colorimetric Assay
Posted by Dr. Yuqi Huang, Assay Development Scientist at Diazyme Laboratories on 25th Jun 2025
Diazyme’s committed to innovations in clinical diagnostics. We are proud to spotlight Lead Scientist Dr. Yuqi Huang’s abstract presentation at ADLM 2025, showcasing the research behind our newly enhanced colorimetric lithium assay. Diazyme has submitted the newly developed assay for FDA’s review.
Dr. Huang’s poster highlights the importance of high precision testing i
…